We’re committed to bringing women more contraceptive choices that can keep pace with their wants and needs. Our pipeline includes both combined hormonal contraception (CHC) and progestin-only transdermal contraceptive products. All of our current product candidates use Skinfusion®, the same patch technology as AG200-15.
Currently, all products beyond AG200-15 are on hold. Depending on the outcome of the initial Phase II clinical trial of the Small Patch (SmP) program, additional design and planning may be required for SmP pipeline products.